Sign In
TARO.US
id: 1189

Taro Pharmaceutical (TARO) $36 Million Shareholder Settlement

Late claims are being considered for compensation, subject to approval.
S.D. New York
Court
1:16-cv-08318
Case number
07/02/2014
Class period Start
11/03/2016
Class period End
08/16/2024
Claim deadline
Taro Pharmaceutical (TARO) agreed to settle $36 million with investors to end claims over hiding generic drug price-fixing that led to a drop in $TARO price upon news of the DOJ antitrust investigation.
Case Status
Accepting Late Claims
Alleged Offence
Misleading Statements, 
Failure to Disclose, 
Omissions
Suspected Party
Directors, 
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
2.53
Filing date
10/25/2016
Plaintiffs
City of Atlanta Firefighters’ Pension Fund
Attorneys
Bernstein Liebhard LLP (New York, NY)
Defendants
Michael Kalb, Kalyanasundaram Subramanian
Judge
Hon. Andrew L. Carter, Jr
Administrator
JND Legal Administration
Settlement agreement date
2024-04-15
Exclusion deadline
08/16/2024
Objection deadline
09/16/2024
Attorney fee
$11,159,397
Trades matching type
FIFO
+$36,000,000
Cash Settlement Amount

Taro Pharmaceutical Industries Ltd

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Cana...

    Ticker
    TARO.US
    ISIN
    USM8737E1084
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Country
    USA
    Address
    14 Hakitor Street, Haifa, Israel, 2624761